Acquisition will enable Agilent to provide a single informatics solution
across laboratory and operational domains

SANTA CLARA, Calif., May 2, 2018
Agilent Technologies, Inc. (NYSE: A) today announced that it has entered into a definitive
agreement to acquire privately-held Genohm, a developer of highly differentiated, on-premise
and cloud-based software solutions for laboratory management.
Genohm’s main laboratory software automation suite, SLIMS, is a digital platform that provides
laboratories with a rapidly deployable and seamless laboratory information management system
(LIMS) and electronic lab notebook (ELN) environment that is used in biobanks, research labs
and next gen sequencing facilities. The platform tracks data and samples, tests and users,
results and workflows, from the original material shipment to the result from lab instruments and
in-silico analysis pipelines. Genohm also has an application marketplace with preconfigured
workflows to enable rapid system implementation across a broad range of industries and
scientific workflows.
Customers are looking to generate better answers, and this requires integrated informatics
solutions. This acquisition enhances Agilent’s current software portfolio, adding LIMS and
workflow management, while expanding ELN capability. This combination will allow Agilent to
bring greater context to analytical data, enabling scientists to generate results more efficiently.
“We were impressed with the team and the technology,” said John Sadler, Vice President and
General Manager of Agilent’s Software and Informatics Division. “The modern architecture of
SLIMS is perfectly aligned with the values of Agilent’s OpenLab products. By integrating this
technology with our broad and diverse instrument portfolio, we are in a unique position to
support and enhance the operations of modern laboratories—truly helping our customers to do
more with their data.”
“Genohm has an excellent footprint in the genomics space,” said Kamni Vijay, Ph.D., Vice
President and General Manager of Agilent’s Genomics Division. “This acquisition supports our
strategy to offer complete next-generation sequencing workflows and improve the laboratory
management of our genomic customers.”
“We are very excited to join the Agilent team and believe that together we can accelerate
development of the digital lab to help our customers advance science and discovery while
ensuring compliance and traceability,” said Frederik Decouttere, founder and CEO of Genohm.
“Our laboratory management platform is highly configurable, easily deployable and leverageable
across many different workflows, which makes our technology a perfect fit for Agilent.”

Headquartered in Lausanne, Switzerland, Genohm has 40 employees.
The transaction is subject to closing conditions. Financial terms of the deal are not being

About Genohm

Genohm, originally founded in Ghent (Belgium) in 2002 as a small two-person bio-informatics
shop, re-established itself in 2011 as an EPFL Start-Up at the Innovation Park in Lausanne
(Switzerland), focusing on guaranteeing compliance, traceability and big lab data management
in highly complex and continuously evolving lab environments. With the successful launch of its
main laboratory software automation suite, SLIMS, Genohm officially entered the lab informatics
market, proudly serving a rapidly growing set of customers in widely varying research and
clinical environments throughout Europe, the Middle East, Asia Pacific and the US. Today,
Genohm has offices in Lausanne, Ghent, and Durham NC and counts a workforce of 40+ highly
trained software and life sciences engineers.  Information about Genohm is available at

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied
chemical markets. With more than 50 years of insight and innovation, Agilent instruments,
software, services, solutions, and people provide trusted answers to its customers’ most
challenging questions. The company generated revenues of $4.47 billion in fiscal 2017 and
employs 14,200 people worldwide. Information about Agilent is available at

Forward-Looking Statements

This news release contains forward-looking statements as defined in the Securities Exchange
Act of 1934 and is subject to the safe harbors created therein. The forward-looking statements
contained herein include, but are not limited to, information regarding Agilent’s future revenue,
earnings and profitability; planned new products; market trends; the future demand for the
company’s products and services; customer expectations; and revenue and non-GAAP
earnings guidance for the second quarter and full fiscal year 2018. These forward-looking
statements involve risks and uncertainties that could cause Agilent’s results to differ materially
from management’s current expectations. Such risks and uncertainties include, but are not
limited to, unforeseen changes in the strength of our customers’ businesses; unforeseen
changes in the demand for current and new products, technologies, and services; unforeseen
changes in the currency markets; customer purchasing decisions and timing, and the risk that
we are not able to realize the savings expected from integration and restructuring activities. In
addition, other risks that Agilent faces in running its operations include the ability to execute
successfully through business cycles; the ability to meet and achieve the benefits of its costreduction goals and otherwise successfully adapt its cost structures to continuing changes in
business conditions; ongoing competitive, pricing and gross-margin pressures; the risk that our
cost-cutting initiatives will impair our ability to develop products and remain competitive and to
operate effectively; the impact of geopolitical uncertainties and global economic conditions on

our operations, our markets and our ability to conduct business; the ability to improve asset
performance to adapt to changes in demand; the ability of our supply chain to adapt to changes
in demand; the ability to successfully introduce new products at the right time, price and mix; the
ability of Agilent to successfully integrate recent acquisitions; the ability of Agilent to successfully
comply with certain complex regulations; and other risks detailed in Agilent’s filings with the
Securities and Exchange Commission, including our quarterly report on Form 10-Q for the first
quarter ended January 31, 2018. Forward-looking statements are based on the beliefs and
assumptions of Agilent’s management and on currently available information. Agilent
undertakes no responsibility to publicly update or revise any forward-looking statement.

NOTE TO EDITORS: Further technology, corporate citizenship and executive news is
available on the Agilent news site at

Agilent Technologies:
Victoria Wadsworth-Hansen (Business)
+1 408 553 2005
+ 45 29336980
Stefanie Notaney (Enterprise)
+1 408 345 8955

Alicia Rodriguez
+1 408 345 8948